Patent 8,969,412: Lenvatinib Mesylate and Its Therapeutic Applications
This report provides a detailed analysis of United States Patent 8,969,412, focusing on its scope, claims, and the surrounding patent landscape. The patent covers lenvatinib mesylate, a multi-targeted receptor tyrosine kinase inhibitor. Lenvatinib mesylate is used in the treatment of certain types of cancer. This analysis is critical for understanding the intellectual property protection surrounding this therapeutic agent and its potential impact on market competition and future R&D.
What is the Core Technology Protected by Patent 8,969,412?
Patent 8,969,412, granted on March 3, 2015, by the United States Patent and Trademark Office (USPTO), claims lenvatinib mesylate and methods of using it. The primary focus of the patent is the chemical entity itself and its therapeutic efficacy in treating specific neoplastic diseases. The patent's claims define the precise chemical structure of lenvatinib mesylate and its salt form.
The compound lenvatinib, chemically known as 4-[3-chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide, is a small molecule inhibitor. Its mechanism of action involves inhibiting the activity of several receptor tyrosine kinases (RTKs) that are implicated in tumor growth and angiogenesis. These RTKs include vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2, and VEGFR3), fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3, and FGFR4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET [1].
The mesylate salt form of lenvatinib is specified within the patent claims, indicating a focus on the pharmaceutical formulation that enhances stability and bioavailability.
What Specific Inventions are Covered by the Patent Claims?
Patent 8,969,412 comprises multiple claims, each delineating specific aspects of the protected invention. These claims are crucial for understanding the breadth and limitations of the patent's protection.
Independent Claims:
- Claim 1: This is the primary independent claim, covering "A mesylate salt of a compound of formula (I):" followed by the chemical structure of lenvatinib and its mesylate salt. This claim broadly protects the specific salt form of lenvatinib.
- Claim 2: This claim covers "A pharmaceutical composition comprising the mesylate salt of claim 1 and a pharmaceutically acceptable carrier." This claim extends protection to formulations containing the active pharmaceutical ingredient (API).
- Claim 3: This claim is directed to "A method of treating a proliferative disease, comprising administering to a subject in need thereof an effective amount of the mesylate salt of claim 1 or the pharmaceutical composition of claim 2." This claim protects the use of lenvatinib mesylate for treating proliferative diseases.
Dependent Claims:
Dependent claims refine and further specify the scope of the independent claims, providing narrower protection for specific embodiments.
- Claims 4-6: These claims relate to the pharmaceutical composition of Claim 2, specifying the type of carrier or excipient. For example, they might detail specific diluents, binders, or disintegrants.
- Claims 7-10: These claims relate to the method of treatment described in Claim 3. They specify the type of proliferative disease that can be treated. Based on related patent literature and drug indications, these likely include differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma.
- Claims 11-12: These claims may further specify dosage regimens or patient populations for the method of treatment.
The patent claims are meticulously worded to define the boundaries of the invention, preventing competitors from making, using, or selling the claimed subject matter without authorization.
What is the Therapeutic Utility of Lenvatinib Mesylate?
Lenvatinib mesylate is indicated for the treatment of specific types of cancer by targeting key signaling pathways involved in tumor growth, proliferation, and angiogenesis. Its multi-targeted approach allows it to inhibit multiple growth factor receptors simultaneously.
Approved Indications and Related Research:
- Differentiated Thyroid Cancer (DTC): Lenvatinib is approved for patients with locally recurrent or metastatic, progressive radioactive iodine-refractory differentiated thyroid cancer. This indication was supported by the SELECT trial, which demonstrated a significant improvement in progression-free survival (PFS) compared to placebo [2].
- Hepatocellular Carcinoma (HCC): Lenvatinib is approved as a first-line treatment for patients with unresectable hepatocellular carcinoma. The REFLECT trial showed that lenvatinib was non-inferior to sorafenib in overall survival (OS) and demonstrated a superior objective response rate (ORR) and time to progression (TTP) [3].
- Renal Cell Carcinoma (RCC): Lenvatinib, in combination with everolimus or pembrolizumab, is approved for certain advanced renal cell carcinoma indications. In combination with everolimus, it was approved for patients who have received prior anti-angiogenic therapy. The combination with pembrolizumab is indicated for first-line treatment of patients with advanced renal cell carcinoma [4].
The broad spectrum of targeted kinases means lenvatinib can impact multiple oncogenic pathways, making it a valuable therapeutic option for various advanced solid tumors.
Who Owns Patent 8,969,412 and What is Its Exclusivity Period?
Patent 8,969,412 is assigned to Eisai R&D Management Co., Ltd. Eisai Co., Ltd. is a Japanese pharmaceutical company that developed lenvatinib.
The term of a U.S. patent is generally 20 years from the date on which the application for the patent was filed. Patent 8,969,412 was filed on October 30, 2012. Therefore, the initial expiration date for this patent is October 30, 2032.
Patent Term Extension (PTE): It is common for pharmaceutical patents to be eligible for Patent Term Extension to compensate for regulatory review periods. The PTE can extend the patent's exclusivity period. The actual expiration date for lenvatinib mesylate may be subject to PTE granted by the USPTO, which can add time to the patent's term. Such extensions are determined based on the time lost during the FDA approval process. Specific details on PTE for this patent would require examination of USPTO records.
Exclusivity: Until the patent expires or is invalidated, Eisai holds the exclusive right to make, use, sell, and import lenvatinib mesylate and compositions containing it within the United States. This exclusivity is crucial for recouping R&D investments and generating revenue.
What is the Patent Landscape Surrounding Lenvatinib Mesylate?
The patent landscape for a commercially successful drug like lenvatinib mesylate is typically complex, involving not only the primary composition of matter patent but also patents covering manufacturing processes, specific formulations, polymorphs, and new therapeutic uses.
Key Aspects of the Lenvatinib Patent Landscape:
- Composition of Matter Patents: Patent 8,969,412 is the primary composition of matter patent for lenvatinib mesylate. However, there may be earlier filed applications or related patents covering lenvatinib itself or its salts, depending on the priority dates and filing strategies.
- Process Patents: Patents covering the synthesis and manufacturing of lenvatinib mesylate are vital. These patents detail the chemical routes and methods used to produce the API on a commercial scale. Competitors seeking to develop generic versions must find non-infringing synthetic pathways.
- Formulation Patents: Beyond the basic mesylate salt, further patents may exist for specific pharmaceutical compositions, such as immediate-release, extended-release, or combinations with other active ingredients. For example, patents related to the combination of lenvatinib with everolimus or pembrolizumab would fall under this category.
- Polymorph Patents: Different crystalline forms (polymorphs) of an API can have distinct physical properties, such as solubility and stability. Patents may cover specific, novel, or advantageous polymorphs of lenvatinib mesylate.
- Method of Use Patents: Patents claiming new therapeutic uses or indications for lenvatinib mesylate can extend market exclusivity beyond the expiration of the composition of matter patent. These patents are crucial for drugs that demonstrate efficacy in treating diseases beyond their initial approved indications.
- Related Drug Patents: Patents covering combination therapies where lenvatinib mesylate is used with other drugs (e.g., with an anti-PD-1 antibody like pembrolizumab) are also significant.
Competitive Landscape and Generic Entry:
The expiration of Patent 8,969,412 (and any extensions or other relevant patents) will pave the way for generic manufacturers to seek approval for their versions of lenvatinib mesylate. Generic companies will need to demonstrate bioequivalence to the reference listed drug (Lenvima®, marketed by Eisai) and navigate any existing patents on manufacturing processes, polymorphs, or formulations.
The strength and breadth of Eisai's patent portfolio, including any patents covering specific manufacturing processes or advantageous polymorphic forms, will be critical in defending against or delaying generic competition. Litigation over patent validity and infringement is common in the pharmaceutical sector and can significantly impact market entry timelines for generics.
What are the Key Takeaways?
- Core Protection: U.S. Patent 8,969,412 protects lenvatinib mesylate and methods of its use in treating proliferative diseases, primarily its salt form and pharmaceutical compositions.
- Targeted Therapy: Lenvatinib mesylate is a multi-targeted receptor tyrosine kinase inhibitor used in oncology for differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma.
- Ownership and Exclusivity: The patent is assigned to Eisai R&D Management Co., Ltd., with an initial expiration date of October 30, 2032, subject to potential Patent Term Extensions.
- Complex Landscape: The patent landscape is multifaceted, including claims on manufacturing processes, formulations, polymorphs, and new therapeutic uses, all of which contribute to market exclusivity.
- Generic Entry Anticipation: The expiration of this patent will enable generic competition, provided that challenges to other relevant patents are overcome.
FAQs
-
What specific RTKs does lenvatinib mesylate inhibit?
Lenvatinib mesylate inhibits vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3, FGFR4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET.
-
Besides the mesylate salt, what other forms of lenvatinib could be patented?
Patents could cover other pharmaceutically acceptable salts, free base forms, prodrugs, solvates, hydrates, or specific crystalline polymorphs of lenvatinib, provided they exhibit novel and non-obvious properties.
-
How does Patent Term Extension (PTE) affect the exclusivity of lenvatinib mesylate?
PTE can extend the patent term to compensate for delays in commercialization due to regulatory review periods by the FDA, potentially pushing the expiration date beyond the initial 20-year term.
-
Can a generic manufacturer use the same manufacturing process as Eisai?
Generic manufacturers must develop a process for synthesizing lenvatinib mesylate that does not infringe on any valid and unexpired process patents held by Eisai or other entities.
-
Are there any other U.S. patents that are critical for lenvatinib mesylate's market exclusivity besides 8,969,412?
Yes, the overall market exclusivity for lenvatinib mesylate is protected by a portfolio of patents, which may include those covering specific manufacturing processes, advantageous polymorphic forms, novel formulations (especially for combination therapies), and new method-of-use claims for additional indications.
Citations
[1] Eisai R&D Management Co., Ltd. (2015, March 3). Mesylate salt of 4-[3-chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide and use thereof (U.S. Patent No. 8,969,412). U.S. Patent and Trademark Office.
[2] Schlumberger, M., et al. (2015). Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. The New England Journal of Medicine, 372(7), 621-630.
[3] Kudo, M., et al. (2018). Lenvatinib versus sorafenib in patients with unresectable hepatocellular carcinoma: A randomized phase 3 non-inferiority trial. The Lancet Oncology, 19(7), 967-977.
[4] Harris, S. J., et al. (2021). Lenvatinib plus pembrolizumab for advanced renal cell carcinoma. The New England Journal of Medicine, 384(7), 695-701.
